|1.||Parkinson Disease (Parkinson's Disease)
11/01/1990 - "CQA 206-291 in Parkinson's disease: an acute single escalating dosage study."
04/01/1991 - "CQA 206-291 in Parkinson's disease."
11/01/1990 - "CQA 206-291, a new ergot derivative with a "biphasic" dopaminergic profile, was studied in 6 patients with longstanding Parkinson's disease suffering from pronounced fluctuations in hourly mobility. "
04/01/1991 - "CQA 206-291, a mixed D1-D2 receptor agonist that also possesses dualistic dopamine antagonist-agonist properties, was investigated in a double-blind, placebo-controlled trial in individuals with Parkinson's disease of moderate severity. "
08/01/1990 - "CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease."
|2.||Pleural Effusion (Pleural Effusions)
|2.||Dopamine Agonists (Dopamine Agonist)
|3.||Levodopa (L Dopa)